Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;5(1):14-9.
doi: 10.4103/0974-1208.97785.

Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation

Yu Li  1 , Dongzi Yang, Qingxue Zhang
Affiliations

Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation

Yu Li et al. J Hum Reprod Sci. 2012 Jan.

Abstract

Objective: Appropriate dosage of the long-acting depot gonadotrophin releasing hormone (GnRH) agonist has not been determined in long protocol for IVF, and one-third-dose depot triptorelin was compared with half-dose in a luteal long protocol of in-vitro fertilization/ intra cytoplasmic sperm injection (IVF/ICSI) treatment in this study.

Materials and methods: This is a prospective, randomized, open clinical trial. 100 patients were randomized into two groups. Group I received one-third-dose (1.25 mg) depot triptorelin. Group II received half-dose (1.87 mg). The clinical and experimental parameters were compared between the two groups.

Results: There was no premature luteinizing hormone (LH) surge in both groups. On Day 3-5 of menstrual cycle after down-regulation, fewer patients showed low-level LH (<1.0 IU/L) and estradiol (<30 pg/mL) in group I (P <0.05). There were fewer oocytes retrieved (P =0.086), fewer total embryos and available embryos for cryopreservation in Group I (P <0.05), while good-quality embryo rate was higher in group I (P <0.05). The length and dose of ovarian stimulation was lower in Group I, but not significantly. The clinical pregnancy (52% versus 40%), implantation (48% versus 37.5%), delivery (46% versus 32%), or live birth (42% versus 32%) rates and the abortion (8% versus 20%) rates showed no significant differences.

Conclusion: Depot triptorelin 1.25 mg can be successfully used with reduced pituitary suppression and lower cost in a long protocol for in-vitro fertilization.

Keywords: GnRH agonist; in-vitro fertilization; ovarian stimulation; triptorelin.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Caspi E, Ron-El R, Golan A, Nachunv A, Herman A, Soffer Y, et al. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotrophin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotrophins. Fertil Steril. 1989;51:95–9. - PubMed
    1. Liu HC, Lai YM, Davis O, Berkeley AS, Graf M, Grifo J, et al. Improved pregnancy outcome with gonadotrophin releasing hormone agonist stimulation is due to the improvement in oocytes quantity rather than quality. J Assist Reprod Genet. 1992;9:338–42. - PubMed
    1. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev. 2005;25:CD002808. - PubMed
    1. Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, et al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Hum Reprod. 1996;11:1169–72. - PubMed
    1. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod. 2000;15:2333–40. - PubMed